AlphAIAlphAI — Financial news for AI agents
medicaldialogues.inOCT 132 min read$TEVA

USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza

Teva, in partnership with Medincell, received USFDA approval for Weltruza, a once-monthly schizophrenia injection. Teva expects to launch the drug in the US soon. Medincell's technology enables extended-release medication. Analysts note potential for improved treatment adherence. Medincell may receive up to $112 million in milestone payments and royalties. Teva's shares rose 2% in Tel Aviv; Medincell's shares gained 16.9% in Paris.

Original reporting
medicaldialogues.in
Published Oct 13, 2026, 11:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 1:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
USFDA Approves Teva's Once-Monthly Schizophrenia Injection Weltruza — source image
Source · medicaldialogues.in
Decision brief

The 30-second read

$TEVABullishHigh
01

Why it matters

The approval expands Teva's psychiatric portfolio and could drive short‑term share gains while highlighting the value of its partnership with Medincell.

02

Market read

A new FDA‑approved schizophrenia treatment adds growth potential for Teva and may influence the broader psychiatric drug sector.

03

What to watch

Potential competition from other long‑acting injectables and pricing negotiations with insurers

Relevance 7/10Novelty 9/10Timing: launch expected in the coming weeks

Background

Teva and French biotech Medincell have partnered on long‑acting injectable technology; Medincell may receive up to $112 million in milestones.

Company-level read

Ticker impact

$TEVABullishHigh confidence
Context

US FDA approved Teva's once‑monthly schizophrenia injection Weltruza, with launch expected in the coming weeks.

Expected impact

likely upward pressure as investors price in the new product launch

Evidence & confidence

FDA approval is a material catalyst; the drug targets a large market and the launch is imminent.

Market effects

Sector

strengthens the long‑acting antipsychotic segment and may benefit peers in psychiatric drugs

Regional

positive for US pharma market; limited impact in Europe

Global

moderate, as the drug addresses a global schizophrenia market

Counterpoint

What could challenge this read

If the drug fails to gain market share or reimbursement, the price impact could be muted

Key entities

  • Company
    Teva Pharmaceutical Industries Ltd.

    US‑listed pharmaceutical company receiving FDA approval for Weltruza.

  • Company
    Medincell

    French biotech partner providing the injectable technology.

Read at source← All news

StoryTeva receives FDA approval for Weltruza, the first once‑monthly subcutaneous olanzapine injection

Also covered by

6 outlets

Related articles

OCT 13
$TEVAHigh

Teva wins FDA approval for schizophrenia injection

Teva Pharmaceuticals received FDA approval for a new injection form of olanzapine, an antipsychotic drug for schizophrenia. The company claims this could improve patient adherence compared to daily oral treatment, potentially reducing relapse risks. Olanzapine is the most widely prescribed atypical antipsychotic.

lifesciencesweden.se1 min
OCT 12
$TEVAHigh

FDA Approves Once-Monthly Olanzapine Injection for Adults with Schizophrenia

The FDA approved Teva Pharmaceuticals' once-monthly olanzapine injection (Weltruza) for adults with schizophrenia. The subcutaneous injection uses novel technology for steady release, eliminating post-injection monitoring. The approval was based on the Phase 3 SOLARIS trial, showing significant symptom reduction and a safety profile consistent with oral olanzapine.

drugtopics.com3 min
OCT 12
$TEVAHigh

FDA Approves First Once-Monthly Subcutaneous Olanzapine LAI for Adults With Schizophrenia

Teva Pharmaceuticals' Weltruza, a once-monthly subcutaneous olanzapine injection, received FDA approval for treating schizophrenia. The treatment requires no loading doses or postinjection monitoring. It will be available in doses of 318 mg, 425 mg, and 531 mg, corresponding to daily oral olanzapine doses. The approval was based on the SOLARIS trial, which showed significant improvements in symptoms compared to placebo.

pharmacytimes.com3 min
OCT 12
$TEVAMed

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva Pharmaceutical Industries received FDA approval for Weltruza, a once-monthly injection for schizophrenia. Shares rose 4.7% on Oct. 9. The drug will launch in the U.S. soon, offering an alternative to daily oral treatments. Teva's Uzedy, another schizophrenia treatment, saw sales surge 51% YoY to $140M in H1 2026. Teva also progresses with its branded pipeline, including duvakitug for inflammatory bowel diseases.

zacks.com6 min
OCT 12
$TEVAMed

Teva wins FDA approval for once-monthly olanzapine injection

Teva Pharmaceuticals received FDA approval for WELTRUZA, a once-monthly olanzapine injection for schizophrenia. Developed with Medincell's SteadyTeq technology, it requires no loading doses or post-injection monitoring. Teva plans a US launch in three strengths. The approval follows positive Phase III trial results, showing symptom improvements and a safety profile consistent with oral olanzapine. Medincell may earn royalties and milestone payments.

manufacturingchemist.com5 min
OCT 12
$TEVAHigh

Morning Rounds: October 5-12

FDA approved Teva's Weltruza, a once-monthly olanzapine injection for schizophrenia, based on phase 3 trial results. Motivista's CT-155, a digital therapeutic, received clearance for negative schizophrenia symptoms. Neurosterix's NTX-253 completed phase 1 and will enter phase 2. Newron's evenamide faces a US trial hold due to 4 deaths in studies.

psychiatrictimes.com2 min